The Artificial Pancreas Research Program is a pioneering clinical research program studying the efficacy of artificial pancreas (AP) systems to improve blood glucose control in people with type 1 diabetes (T1D) is underway at the Icahn School of Medicine at Mount Sinai. Under the leadership of Carol Levy, MD, Associate Professor of Medicine, Endocrinology, Diabetes and Bone Disease and Director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, the Artificial Pancreas Research Program is studying one of the most promising breakthroughs in type 1 diabetes treatment in decades.
Mount Sinai’s research in this area has the potential to revolutionize the management of type 1 diabetes by paving the way for people with type 1 diabetes to use AP systems at home. Strong initial results have led to more studies supporting FDA approval. “The Artificial Pancreas Program at Mount Sinai holds the promise of freeing the patient from the burdens involved in self-care on a minute to minute basis, including frequent finger stick testing, careful monitoring of glucose sensor data, and regularly making insulin dose adjustments to reduce the risk of both high and low blood sugar levels,” says Dr. Levy. “In short, these devices have the potential to result in better quality of life for people with T1D.”